No Data
Do Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Earnings Warrant Your Attention?
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Bailong Chuangyuan: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Bailong Chuangyuan (605016.SH) performance report: In 2024, the net income is 0.249 billion yuan, a year-on-year increase of 29.20%.
On February 17, Gelonghui announced that Bailong Chuangyuan (605016.SH) released its 2024 annual performance report. In 2024, the company's production and operation were normal, and both domestic and overseas businesses were conducted smoothly, achieving a certain degree of growth in revenue and profit. In 2024, the company achieved total operating revenue of 1.152 billion yuan, a year-on-year increase of 32.64%; the Net income attributable to the shareholders of the listed company was 0.249 billion yuan, a year-on-year increase of 29.20%; the Net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.235 billion yuan, a year-on-year increase of 33.64%; the main reason being: 1. Increased demand from domestic and overseas clients.
Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Stalled
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Not Flying Under The Radar
